Stocktoria
RenovoRx, Inc. RNXT
RenovoRx, Inc. (RNXT) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.1M at a -994.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | 3/9 | — | — | — |
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
FAQ
Is RNXT financially healthy?
RenovoRx, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does RNXT pay a dividend?
No, RenovoRx, Inc. does not currently pay a dividend.
How profitable is RNXT?
In FY2025, RenovoRx, Inc. had a net margin of -994.5% and a return on equity of -206.0%.
What is the analyst price target for RNXT?
The average Wall-Street price target for RenovoRx, Inc. is $7.03, about 527.7% above the recent price, from 4 analysts.
Is RNXT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RenovoRx, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.